This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Cancer Care Ontario, Mcgill University. Active years: 2012.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 2 
1 out of 570 
Years Active: 2012
Title: The Innovations of Phillippe Laflamme
Introduction
Phillippe Laflamme is a notable inventor based in Montreal, Canada. He has made significant contributions to the field of medical research, particularly in the assessment of cancer risk. His work focuses on identifying individuals at altered risk for developing colorectal cancer.
Latest Patents
Laflamme holds a patent for a method that involves detecting a single nucleotide polymorphism (SNP) to assess the risk of colorectal cancer. This innovative approach has the potential to improve early detection and prevention strategies for this prevalent disease. He has 1 patent to his name.
Career Highlights
Throughout his career, Laflamme has worked with esteemed organizations such as Cancer Care Ontario and McGill University. His experience in these institutions has allowed him to collaborate with leading experts in the field of cancer research.
Collaborations
Laflamme has had the opportunity to work alongside notable colleagues, including Michelle Cotterchio and Steven Gallinger. Their combined expertise has contributed to advancements in understanding cancer risk factors.
Conclusion
Phillippe Laflamme's innovative work in cancer risk assessment highlights the importance of early detection and personalized medicine. His contributions continue to influence the field and pave the way for future research in colorectal cancer.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile